Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial
Table 1
Main demographic and clinical features of the two groups.
Variable
Danlou Tablet group ()
Placebo group ()
()
value
Age, yr
0.04
0.44
Men, number (%)
72 (66.1)
74 (67.3)
0.04
0.85
Body weight, kg
0.55
Height, cm
0.82
Family history of coronary disease, number (%)
18 (16.5)
10 (9.1)
2.71
0.10
Concomitant diseases, number (%)
Previous coronary heart disease
41 (37.6)
47 (42.7)
0.60
0.44
Previous coronary intervention
9 (8.3)
17 (15.5)
2.71
0.10
Systemic hypertension
51 (46.8)
63 (57.3)
2.41
0.12
Diabetes mellitus
21 (19.3)
19 (17.3)
0.15
0.70
Dyslipidemia
38 (34.9)
38 (34.5)
0.002
0.96
Heart failure
1 (0.9)
4 (3.6)
0.3
Arrhythmia
4 (3.7)
10 (9.1)
2.69
0.10
Stroke
7 (6.4)
8 (7.3)
0.06
0.80
Current smoker, number (%)
47 (43.1)
44 (40.0)
0.22
0.64
Cardiac Marker Elevation, number (%)
30 (27.5%)
33 (30.0%)
0.16
0.69
Clinical pattern, number (%)
Unstable angina
88 (80.7)
87 (79.1)
0.09
0.76
NSTEMI
21 (19.3)
23 (20.9)
Cardiac function, number (%)
Level I
41 (37.6)
41 (37.3)
0.03
0.99
Level II
53 (48.6)
53 (48.2)
Level III
15 (13.8)
16 (14.5)
Values are given as number of patients (%) or mean ± SD. NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; ACE, angiotensin-converting enzyme; and ARB, angiotensin II receptor blocker. value is from Fisher’s exact test.
